AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04727684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study NCT04727684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study NCT04727684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
Study NCT04727684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
Study NCT01931228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MI-E plus manually assisted coughing
Description: MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
Study NCT01931228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manually assisted coughing
Description: Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
Study NCT02327507 — intervention group
Intervention type: BEHAVIORAL
Intervention: Toothpaste & Telephone Support
Description: Mailed toothpaste, messages and telephone support.
Study NCT03158025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo zolpidem
Description: Placebo 3 x 10 mg zolpidem tablets will be administered orally.
Study NCT02597582 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neck dissection
Description: The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
Study NCT02597582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neck dissection
Description: The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
Study NCT04130178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: block of the digital nerves in rheumatoid arthritis patient
Study NCT04130178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: subcutaneous saline injection
Study NCT00389779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan capsules administered orally once daily
Study NCT00389779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Guanfacine capsules administered orally once daily
Study NCT00389779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily
Study NCT00389779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily
Study NCT00389779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily
Study NCT04281394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted gait training
Description: SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
Study NCT04281394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional gait training
Description: even level gait training and range of motion exercises
Study NCT03138902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TRUTOL Glucose Tolerance Beverage
Description: A caffeine-free, non-carbonated, glucose tolerance beverage
Study NCT00253981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic Near-Infrared Light Energy (MIRE)
Description: Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
Study NCT00253981 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Monochromatic Near-Infrared Light Energy (MIRE)
Description: Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
Study NCT04480801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermal Evaluation and Foot Care
Description: Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
Study NCT04480801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Foot Care
Description: Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
Study NCT03158025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suvorexant
Description: Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
Study NCT00494780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
Study NCT00494780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone, Prednisone or equivalent
Description: 100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
Study NCT06110416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nausea relief inhaler
Description: Aromatherapy and essential oils are an alternative method to controlling post-operative nausea and vomiting after post-surgical intervention.
Study NCT03460756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Oral
Study NCT03460756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03503175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel urinary access system (CystoSureTM)
Description: CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
Study NCT03503175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Foley catheter
Description: Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
Study NCT01122771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B
Description: Ambisome i.v. 5mg on days 1, 3 and 5
Study NCT01122771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal amphotericin B + miltefosine
Description: Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
Study NCT01122771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal amphotericin B + paromomycin
Description: Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Study NCT01122771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine + Paromomycin
Description: Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Study NCT02753114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
Study NCT02753114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intranasal Normal Saline administered via mucosal atomization device.
Study NCT03724032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS*
Description: Non-invasive brain stimulation (active protocol)
Study NCT05487716 — intervention group
Intervention type: BEHAVIORAL
Intervention: High-intensity interval training (HIIT)
Description: Included subjects who underwent an additional 36 sessions (2-3 sessions per week) of supervised bicycle ergometer (Ergoselect 150P, ergoline GmbH, Germany) training as in the previous protocol5 were classified as the HIIT participant. They exercised alternatively at 3-min interval of 80% VO2peak and 3-min interval of 40% VO2peak for 30 min each session.
Study NCT03724032 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS*
Description: Non-invasive brain stimulation (sham protocol)
Study NCT00783237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
Study NCT00783237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray, single dose of 2 sprays per nostril
Study NCT02656537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnSite™ HD Grid Catheter mapping system
Study NCT04219007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide
Description: After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
Study NCT00072566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00072566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study NCT03396692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient-controlled analgesia (PCA)
Description: Group 1 control:~* Morphine titration at 0.1 mg/kg~* Establishment of PCA morphine:~* concentration 1mg/ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg
Study NCT03396692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Block of the posterior exo-thoracic fascia with Ropivacaine
Description: Group 2 PEF block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.
Study NCT03396692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Block of paravertebral space with Ropivacaine
Description: Group 3 paravertebral block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse.
Study NCT01899027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
Study NCT01899027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
Study NCT02874430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given orally
Study NCT02874430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Given orally
Study NCT00001304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic Human Parathyroid Hormone 1-34
Description: twice daily subcutaneous injections
Study NCT00072566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02937675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib (eFT-508)
Description: eFT508
Study NCT02545556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HepaSphere combined with cryosurgery
Description: liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
Study NCT01904734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
Study NCT02938052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PP-based health behavior intervention
Description: The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
Study NCT02545556 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HepaSphere combined with cryosurgery
Description: liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
Study NCT01490749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
Study NCT01490749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Patients will receive two cycles of XELOX.
Study NCT01490749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given on a 3 weeks on and 1 week off schedule.
Study NCT01490749 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
Study NCT00001304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol & Calcium
Description: Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
Study NCT03284086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: upper-body double-poling
Description: An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
Study NCT04427371 — intervention group
Intervention type: OTHER
Intervention: the levels of pyroptosis
Description: Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
Study NCT03284086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: arm crank ergometry
Description: An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
Study NCT04523324 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublok™ Quadrivalent by Sanofi, Inc.
Description: 0.5 mL intramuscular dose of Flublok
Study NCT04523324 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VaxigripTetra™ by Sanofi, Inc.
Description: 0.5 mL intramuscular dose of Vaxigrip
Study NCT04394338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia
Description: to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
Study NCT03245034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture Therapy
Description: Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG).
Study NCT01582919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuroimaging
Study NCT01582919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Study NCT01272921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Varying doses to determine the duration of analgesia
Study NCT00192569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alfa 2a
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
Study NCT00192569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (HIV conifected patients only)
Description: * genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
Study NCT05334966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Hyperoxygenation
Description: Oxygen is given to mothers at 8L through a non-rebreather mask.
Study NCT05334966 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maternal Hyperoxygenation
Description: Oxygen is given to mothers at 8L through a non-rebreather mask.
Study NCT01760629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecotherm-HELIX
Description: Whole body cooling using Tecotherm-HELIX
Study NCT01012193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol 100mg bid or clopidogrel 150-mg daily
Description: Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
Study NCT04771052 — intervention group
Intervention type: OTHER
Intervention: COVID Rehabilitation Program for the Elderly (CORE)
Description: In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
Study NCT00494871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] >= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
Study NCT00494871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients >70 years and 2.0-3.0 for patients \<70 years)
Study NCT00494871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban placebo
Description: Participants orally administered a rivaroxaban placebo tablet
Study NCT00494871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin placebo
Description: Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
Study NCT01829802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir boosted Atazanavir
Description: Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
Study NCT01829802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir boosted Atazanavir
Description: Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
Study NCT01829802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
Study NCT01829802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC (or 3TC)
Description: Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day